BlackRock’s Vigil Neuroscience VIGL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-415,316
| Closed | -$3.3M | – | 5612 |
|
|
2025
Q2 | $3.3M | Sell |
415,316
-3,829
| -0.9% | -$17.2K | ﹤0.01% | 3928 |
|
|
2025
Q1 | $746K | Sell |
419,145
-1,557
| -0.4% | -$3.5K | ﹤0.01% | 4277 |
|
|
2024
Q4 | $715K | Sell |
420,702
-1,845
| -0.4% | -$5.45K | ﹤0.01% | 4313 |
|
|
2024
Q3 | $1.44M | Buy |
422,547
+17,504
| +4% | +$64.8K | ﹤0.01% | 4091 |
|
|
2024
Q2 | $1.62M | Sell |
405,043
-471,989
| -54% | -$1.62M | ﹤0.01% | 4026 |
|
|
2024
Q1 | $2.99M | Sell |
877,032
-42,100
| -5% | -$131K | ﹤0.01% | 3862 |
|
|
2023
Q4 | $3.11M | Buy |
919,132
+71,853
| +8% | +$370K | ﹤0.01% | 3876 |
|
|
2023
Q3 | $4.57M | Buy |
847,279
+25,827
| +3% | +$178K | ﹤0.01% | 3691 |
|
|
2023
Q2 | $7.72M | Buy |
821,452
+719,366
| +705% | +$6.8M | ﹤0.01% | 3536 |
|
|
2023
Q1 | $999K | Sell |
102,086
-305
| -0.3% | -$3.43K | ﹤0.01% | 4335 |
|
|
2022
Q4 | $1.28M | Buy |
102,391
+666
| +0.7% | +$8.18K | ﹤0.01% | 4327 |
|
|
2022
Q3 | $926K | Sell |
101,725
-2,498
| -2% | -$18.3K | ﹤0.01% | 4503 |
|
|
2022
Q2 | $269K | Sell |
104,223
-199,466
| -66% | -$788K | ﹤0.01% | 4956 |
|
|
2022
Q1 | $2.13M | Buy |
+303,689
| New | +$4.01M | ﹤0.01% | 4361 |
|
Other funds holding VIGL
BlackRock's VIGL Position: Q3 2025 in Review
BlackRock sold out of Vigil Neuroscience (VIGL) in Q3 2025, closing a stake of 415,316 shares — an estimated $3.3M sold.
BlackRock first reported a position in VIGL in Q1 2022 and held it in 14 quarters. The position peaked at $7.72M in Q2 2023. 2 funds tracked by Wall St. Rank hold VIGL as of Q3 2025.
- BlackRock reported no remaining Vigil Neuroscience position as of Q3 2025 after selling out during the quarter.
- BlackRock sold 415,316 Vigil Neuroscience shares in Q3 2025, an estimated $3.3M.
- BlackRock first reported a position in Vigil Neuroscience in Q1 2022 and held it in 14 quarters.
- BlackRock's Vigil Neuroscience position peaked at $7.72M in Q2 2023.
- 2 funds tracked by Wall St. Rank held Vigil Neuroscience as of Q3 2025.
Based on BlackRock's 13F filing for Q3 2025, filed 12 Nov 2025.